Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

被引:27
|
作者
Castelli, Germana [1 ]
Pelosi, Elvira [1 ]
Testa, Ugo [1 ]
机构
[1] Ist Super Sanita, Dept Oncol, Viale Regina Elena 299, I-00161 Rome, Italy
关键词
apoptosis; acute myeloid leukemia; leukemia; TRAIL; BCL-2; MCL-1; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; FATTY-ACID OXIDATION; TRAIL-INDUCED APOPTOSIS; INTEGRATED STRESS-RESPONSE; BCL-2 FAMILY PROTEINS; SENSITIZES AML CELLS; MULTICENTER PHASE-II; CLONAL HEMATOPOIESIS; STEM-CELLS;
D O I
10.3390/cancers11020260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute Myelogenous Leukemia (AML) is a malignant disease of the hematopoietic cells, characterized by impaired differentiation and uncontrolled clonal expansion of myeloid progenitors/precursors, resulting in bone marrow failure and impaired normal hematopoiesis. AML comprises a heterogeneous group of malignancies, characterized by a combination of different somatic genetic abnormalities, some of which act as events driving leukemic development. Studies carried out in the last years have shown that AML cells invariably have abnormalities in one or more apoptotic pathways and have identified some components of the apoptotic pathway that can be targeted by specific drugs. Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. TNF-related apoptosis-inducing ligand (TRAIL) and its receptors are frequently deregulated in AML patients and their targeting may represent a promising strategy for development of new treatments. Altered mitochondrial metabolism is a common feature of AML cells, as supported through the discovery of mutations in the isocitrate dehydrogenase gene and in mitochondrial electron transport chain and of numerous abnormalities of oxidative metabolism existing in AML subgroups. Overall, these observations strongly support the view that the targeting of mitochondrial apoptotic or metabolic machinery is an appealing new therapeutic perspective in AML.
引用
收藏
页数:77
相关论文
共 50 条
  • [1] Targeting mitochondrial metabolism in acute myeloid leukemia
    Rex, Madison Rush
    Williams, Robert
    Birsoy, Kivanc
    Llman, Martin S. Ta
    Stahl, Maximillian
    LEUKEMIA & LYMPHOMA, 2022, 63 (03) : 530 - 537
  • [2] An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism
    Saxena, Kapil
    Konopleva, Marina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 973 - 988
  • [3] Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia
    Schimmer A.D.
    Current Treatment Options in Oncology, 2007, 8 (4) : 277 - 286
  • [4] Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells
    Murphy, Lindsey A.
    Winters, Amanda C.
    BIOMEDICINES, 2023, 11 (12)
  • [5] Emerging therapies for acute myeloid leukemia
    Caner Saygin
    Hetty E. Carraway
    Journal of Hematology & Oncology, 10
  • [6] Emerging therapies for acute myeloid leukemia
    Saygin, Caner
    Carraway, Hetty E.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [7] Current and Emerging Therapies for Acute Myeloid Leukemia
    Robak, Tadeusz
    Wierbowska, Agnieszka
    CLINICAL THERAPEUTICS, 2009, 31 : 2349 - 2370
  • [8] Novel emerging therapies in atherosclerosis targeting lipid metabolism
    Gupta, Manasvi
    Blumenthal, Colin
    Chatterjee, Subhankar
    Bandyopadhyay, Dhrubajyoti
    Jain, Vardhmaan
    Lavie, Carl J.
    Virani, Salim S.
    Ray, Kausik K.
    Aronow, Wilbert S.
    Ghosh, Raktim K.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (06) : 611 - 622
  • [9] The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism
    Stuhldreier, Fabian
    Schmitt, Laura
    Lenz, Thomas
    Hinxlage, Ilka
    Zimmermann, Marcel
    Wollnitzke, Philipp
    Schliehe-Diecks, Julian
    Liu, Yang
    Jaeger, Paul
    Geyh, Stefanie
    Teusch, Nicole
    Peter, Christoph
    Bhatia, Sanil
    Haas, Rainer
    Levkau, Bodo
    Reichert, Andreas S.
    Stuehler, Kai
    Proksch, Peter
    Stork, Bjoern
    Wesselborg, Sebastian
    CELL DEATH & DISEASE, 2022, 13 (11)
  • [10] Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)
    Lappin, Katrina
    Matchett, Kyle B.
    Blayney, Jaine
    Mills, Ken I.
    BLOOD, 2018, 132